The FDA granted Priority Review for the NDA of DCCR in PWS. Could you explain the significance of this designation, particularly for a condition as challenging as Prader-Willi Syndrome?

Given that hyperphagia is a hallmark and life-threatening symptom of PWS, how could DCCR's ability to address hyperphagia change the standard of care for these patients?

Beyond hyperphagia, DCCR has shown promise in addressing other PWS symptoms such as aggressive behaviors and metabolic parameters. How important is it to have a treatment that can potentially address multiple aspects of this complex syndrome?

Developing treatments for rare diseases like PWS can be particularly challenging. What are some of the key hurdles that DCCR has successfully overcome in its clinical development, and what challenges remain?

Currently, there are no approved therapies for hyperphagia in PWS. How does DCCR compare to other management strategies that are currently used off-label or in clinical practice?

The FDA has planned an Advisory Committee meeting to discuss the application for DCCR. What are the potential implications of this meeting for the approval process, and what key points do you expect to be discussed?

The PWS community has shown strong support for the development of DCCR. From your perspective, how might the approval of DCCR impact the daily lives of patients and their families?

With a PDUFA target action date set for December 27, 2024, what are the next steps in the regulatory process, and how might the approval of DCCR reshape the treatment landscape for Prader-Willi Syndrome both in the U.S. and potentially internationally?

What are the impediments to using a generic source of diazoxide choline?